# Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).

> **NCT03242590** · PHASE3 · COMPLETED · sponsor: **Lipocine Inc.** · enrollment: 95 (actual)

## Conditions studied

- Hypogonadism, Male

## Interventions

- **DRUG:** LPCN 1021

## Key facts

- **NCT ID:** NCT03242590
- **Lead sponsor:** Lipocine Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2017-03
- **Final completion:** 2017-07
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2019-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03242590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03242590, "Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03242590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*